| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 69097-0830-37 | 69097-0830 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 5, 2019 | In Use | |
| 51655-0813-54 | 51655-0813 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 10, 2021 | In Use | |
| 68788-9670-01 | 68788-9670 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 24, 2013 | In Use | |
| 70518-3512-00 | 70518-3512 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 7, 2022 | In Use | |
| 50436-0133-01 | 50436-0133 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 2, 2007 | In Use | |
| 70518-1585-04 | 70518-1585 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 9, 2023 | Jul 3, 2025 | In Use |
| 67046-1029-03 | 67046-1029 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 11, 2024 | In Use | |
| 70518-3512-08 | 70518-3512 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 24, 2025 | In Use | |
| 68788-9402-03 | 68788-9402 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 12, 2012 | In Use | |
| 70518-3512-02 | 70518-3512 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 20, 2023 | Feb 19, 2025 | In Use |
| 61314-0304-10 | 61314-0304 | filgrastim-sndz | Zarxio | 300.0 ug/.5mL, 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Sep 3, 2015 | Feb 28, 2021 | No Longer Used |
| 68084-0921-25 | 68084-0921 | Cyclosporine | Cyclosporine | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Nov 3, 2015 | In Use | |
| 00069-0291-10 | 00069-0291 | filgrastim-aafi | Nivestym | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sep 24, 2018 | In Use | |
| 51662-1514-01 | 51662-1514 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 31, 2020 | In Use | |
| 16714-0815-01 | 16714-0815 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 30, 2018 | Aug 31, 2025 | No Longer Used | |
| 00093-7355-01 | 00093-7355 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 15, 2006 | Aug 5, 2013 | In Use |
| 54868-3084-00 | 54868-3084 | Dronabinol | Marinol | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Aug 11, 1994 | Mar 31, 2014 | No Longer Used | |
| 51672-4138-00 | 51672-4138 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 28, 2010 | May 28, 2010 | In Use |
| 70518-3512-04 | 70518-3512 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 20, 2023 | Dec 7, 2024 | In Use |
| 42291-0280-10 | 42291-0280 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 31, 2014 | Feb 5, 2015 | In Use |
| 70518-3512-05 | 70518-3512 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 23, 2023 | In Use | |
| 69539-0181-01 | 69539-0181 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb 10, 2020 | In Use | |
| 60760-0306-10 | 60760-0306 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 1, 2016 | In Use | |
| 65162-0691-19 | 65162-0691 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 17, 2010 | In Use | |
| 55700-0484-20 | 55700-0484 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 13, 2017 | In Use |
Found 12159 results — Export these results
Home